CN114555081A - 用于治疗癫痫或用于治疗自闭症谱系障碍的外用剂 - Google Patents

用于治疗癫痫或用于治疗自闭症谱系障碍的外用剂 Download PDF

Info

Publication number
CN114555081A
CN114555081A CN202080072265.6A CN202080072265A CN114555081A CN 114555081 A CN114555081 A CN 114555081A CN 202080072265 A CN202080072265 A CN 202080072265A CN 114555081 A CN114555081 A CN 114555081A
Authority
CN
China
Prior art keywords
sirolimus
external preparation
treating
autism spectrum
epilepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080072265.6A
Other languages
English (en)
Chinese (zh)
Inventor
金田真理
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Publication of CN114555081A publication Critical patent/CN114555081A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080072265.6A 2019-10-16 2020-10-07 用于治疗癫痫或用于治疗自闭症谱系障碍的外用剂 Pending CN114555081A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-189091 2019-10-16
JP2019189091 2019-10-16
PCT/JP2020/037986 WO2021075328A1 (ja) 2019-10-16 2020-10-07 てんかん治療用又は自閉症スペクトラム障害治療用外用剤

Publications (1)

Publication Number Publication Date
CN114555081A true CN114555081A (zh) 2022-05-27

Family

ID=75537453

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080072265.6A Pending CN114555081A (zh) 2019-10-16 2020-10-07 用于治疗癫痫或用于治疗自闭症谱系障碍的外用剂

Country Status (7)

Country Link
US (1) US20240058365A1 (https=)
EP (1) EP4046637A4 (https=)
JP (1) JP7601398B2 (https=)
CN (1) CN114555081A (https=)
AU (1) AU2020365665A1 (https=)
CA (1) CA3153921A1 (https=)
WO (1) WO2021075328A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130317053A1 (en) * 2011-01-31 2013-11-28 Osaka University Externally-used drug for treating skin disorder and method for producing same
CN104490873A (zh) * 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526889A (ja) * 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
JP6541124B2 (ja) * 2015-03-23 2019-07-10 国立大学法人大阪大学 びまん性神経線維腫用の外用薬
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130317053A1 (en) * 2011-01-31 2013-11-28 Osaka University Externally-used drug for treating skin disorder and method for producing same
CN104490873A (zh) * 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
（美）斯考特.W.阿特拉斯: "《中枢神经系统磁共振成像》", 31 January 2008, pages: 375 *
傅超美: "《中药药剂学》", 31 August 2018, pages: 204 *
陈德宇主编: "《中西医结合皮肤性病学 供中西医临床医学专业用》", 31 August 2012, pages: 315 - 319 *

Also Published As

Publication number Publication date
AU2020365665A1 (en) 2022-04-14
WO2021075328A1 (ja) 2021-04-22
JPWO2021075328A1 (https=) 2021-04-22
JP7601398B2 (ja) 2024-12-17
EP4046637A4 (en) 2023-11-01
CA3153921A1 (en) 2021-04-22
US20240058365A1 (en) 2024-02-22
EP4046637A1 (en) 2022-08-24

Similar Documents

Publication Publication Date Title
CN111670036B (zh) 包含托法替尼的局部调配物
JP5135441B2 (ja) タクロリムス外用剤
KR101651448B1 (ko) 체지방을 국소적으로 증가시키는 방법 및 조성물
KR20200058402A (ko) 수-혼화성, 약학적으로 허용가능한 용매의 수성 혼합물 내 로플루밀라스트의 약학 조성물
TR201815573T4 (tr) Topikal olarak uygulanabilir farmasötik preparasyon.
JP2000143507A (ja) カプサイシン含有外用剤
AU2017247963A1 (en) Topical composition comprising tacrolimus
WO2022178983A1 (zh) 一种天然药物的外用制剂、制备方法及其应用
EP3275441B1 (en) External medicine for diffuse plexiform neurofibroma
WO2023016583A1 (zh) 一种芦可替尼组合物及其用途
JPH07557B2 (ja) 皮膚炎に対する治療用組成物
JP2011102260A (ja) タクロリムス外用剤
KR101018819B1 (ko) 티오우레아 유도체를 함유하는 소양성 또는 자극성피부질환의 예방 또는 치료용 외용제 조성물
JP7601398B2 (ja) てんかん治療用又は自閉症スペクトラム障害治療用外用剤
HK40065801A (zh) 用於治疗癫痫或用於治疗自闭症谱系障碍的外用剂
JP2024535105A (ja) ルキソリチニブ組成物およびその調製方法
EP3932487A1 (en) External preparation for vascular abnormality treatment
JP7446711B2 (ja) 皮膚外用組成物
RU2426540C1 (ru) Противовоспалительное и противоаллергическое лекарственное средство и фармацевтическая композиция на его основе
WO2020184128A1 (ja) シロリムスまたはその誘導体を含有する局所適用外用剤
JP7514598B2 (ja) 皮膚外用組成物
JP5722364B2 (ja) 医薬組成物
JP7520810B2 (ja) 医薬製剤
WO2019002367A1 (en) TOPICAL COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES
KR20260006651A (ko) 안정성이 개선된 페놀 유도체의 약학적 조성물 및 그의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40065801

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20220527

RJ01 Rejection of invention patent application after publication